EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

What a Surgeon Needs to Know about Cytoreductive Nephrectomy in the Immunotherapy Era: A Comprehensive Narrative Review

Markos Karavitakis, Filippos Nikitakis, Christos Zabaftis, Nikolaos Grivas, Maria Chalkidou, Smaragda Tsela, Athanasios Bouchalakis, Ilias Kanakakis, Sotiria Tsogka, Maria Rempelou, Vasiliki Bakalaki, Markos Karavitakis

Medical Research Archives · 08.06.2026 · 14 (5)

DOI: 10.18103/mra.2026.0247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 08.06.2026. Verfasst von Markos Karavitakis und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytoreductive nephrectomy in metastatic renal cell carcinoma has been redefined by the results of the CARMENA and SURTIME trials and, more recently, by the introduction of immune checkpoint inhibitor-based combination regimens. Although systemic therapy has improved survival outcomes, important uncertainty remains regarding patient selection, timing of surgery, operative strategy, and postoperative integration of cytoreductive nephrectomy within multimodal care. This narrative review summarizes contemporary evidence on cytoreductive nephrectomy in the immunotherapy era, with a focus on patient selection, treatment sequencing, surgical management, and postoperative decision-making. Current real-world, registry-based, and meta-analytic data suggest that cytoreductive nephrectomy may still have a role in carefully selected patients, particularly those with favorable or selected intermediate-risk disease, limited metastatic burden, preserved performance status, and disease control after initial systemic therapy. Deferred cytoreductive nephrectomy has gained increasing attention as a response-adapted strategy that may allow biologic selection of patients more likely to benefit from surgery, whereas upfront cytoreductive nephrectomy may still be appropriate in selected favorable-risk cases or when local symptom control is required. Radical nephrectomy remains the standard surgical approach for most patients, while partial nephrectomy and minimally invasive techniques may be considered in highly selected settings. However, most available evidence remains retrospective and subject to important bias. Overall, cytoreductive nephrectomy should be regarded as a selective, risk-adapted, and strategically timed component of multidisciplinary metastatic renal cell carcinoma management in the immunotherapy era, although its optimal role remains to be defined by ongoing prospective trials.

Zitieren

APA

Karavitakis, M., Nikitakis, F., Zabaftis, C., Grivas, N., Chalkidou, M., Tsela, S., Bouchalakis, A., Kanakakis, I., Tsogka, S., Rempelou, M., Bakalaki, V., & Karavitakis, M. (2026). What a Surgeon Needs to Know about Cytoreductive Nephrectomy in the Immunotherapy Era: A Comprehensive Narrative Review. Medical Research Archives, 14(5). https://doi.org/10.18103/mra.2026.0247

Vancouver

Karavitakis M, Nikitakis F, Zabaftis C, Grivas N, Chalkidou M, Tsela S, et al. What a Surgeon Needs to Know about Cytoreductive Nephrectomy in the Immunotherapy Era: A Comprehensive Narrative Review. Medical Research Archives. 2026;14(5). doi:10.18103/mra.2026.0247

BibTeX
@article{Karavitakis2026,
  author = {Karavitakis, Markos and Nikitakis, Filippos and Zabaftis, Christos and Grivas, Nikolaos and Chalkidou, Maria and Tsela, Smaragda and Bouchalakis, Athanasios and Kanakakis, Ilias and Tsogka, Sotiria and Rempelou, Maria and Bakalaki, Vasiliki and Karavitakis, Markos},
  title = {What a Surgeon Needs to Know about Cytoreductive Nephrectomy in the Immunotherapy Era: A Comprehensive Narrative Review},
  journal = {Medical Research Archives},
  year = {2026},
  volume = {14},
  number = {5},
  doi = {10.18103/mra.2026.0247}
}
Kostenlos starten →